Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:acquisitionYear |
2023
|
| gptkbp:CEO |
gptkb:Kevin_Judice
|
| gptkbp:developedBy |
oral small molecule drugs
|
| gptkbp:focusesOn |
immunology
oral therapeutics |
| gptkbp:foundedYear |
2013
|
| gptkbp:headquartersLocation |
gptkb:South_San_Francisco,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
DICE Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:DC-806
gptkb:DC-853 |
| gptkbp:platform |
gptkb:DELSCAPE
|
| gptkbp:stockSymbol |
gptkb:DICE
|
| gptkbp:target |
autoimmune diseases
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
https://www.dicetherapeutics.com/
|
| gptkbp:bfsParent |
gptkb:Eli_Lilly
|
| gptkbp:bfsLayer |
6
|